CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 536 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
0.15% Azelastine Hydrochloride 822 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00660829
NCT00660829Phase 3Completed
CompareCT.gov

Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis

Meda Pharmaceuticals·interventional·Posted Apr 17, 2008·Updated Apr 13, 2015

In Brief

A Phase 3 clinical trial evaluating Placebo and 0.15% Azelastine Hydrochloride for Seasonal Allergic Rhinitis. Completed, enrolled 536 participants across 6 sites.

Detailed Summary

The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 17, 2008
Enrollment StartDec 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.2 years ago

Interventions

Placebodrug

Placebo

0.15% Azelastine Hydrochloridedrug

0.15% Azelastine Hydrochloride 822 mcg